Masimo to be acquired by Danaher for $180.00 per share in cash

Masimo (MASI) announced that it has entered into a definitive agreement pursuant to which Danaher (DHR) will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9B. The transaction has been unanimously approved by both Masimo’s board of directors and Danaher’s board of directors. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings. The Transaction is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals. It is expected to close in the second half of 2026.